Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 36 Neoplasms 8 HER2-positive Breast Cancer 4 Triple Negative Breast Neoplasms 3 Neoplasm Metastasis 3 Salivary Gland Neoplasms 2 Pathologic Complete Response 2 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Hematologic Neoplasms 2 HER2-positive Early Breast Cancer 2 Endometrial Neoplasms 2 Colonic Neoplasms 2 Anatomic Stage I Breast Cancer AJCC v8 2 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Skin Neoplasms 1 Resectable HER2-positive Breast Cancer 1 Recurrence 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplastic Cells, Circulating 1 Neoplasms by Site 1 Neoplasms by Histologic Type 1 Lymphoproliferative Disorders 1 Lung Neoplasms 1 Liver Neoplasms 1 Hemangiosarcoma 1 Heart Failure 1

Interventions

pertuzumab 1 azeliragon 1 Trastuzumab 1 Docetaxel 1 Cyclophosphamide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Cancer Related Cognitive Decline × pertuzumab × Clear all

NCT05256745 2025-12-24

RAGE

Georgetown University

Phase 1/2 Recruiting

Cancer Related Cognitive Decline

Data powered by HemOnc (CC BY 4.0) Colophon ⚡